Citation for published version (APA): Paramarta, J. E. (2014). Spondyloarthritis: From disease phenotypes to novel treatments

Transcription

1 UvA-DARE (Digital Academic Repository) Spondyloarthritis: From disease phenotypes to novel treatments Paramarta, Jacky Link to publication Citation for published version (APA): Paramarta, J. E. (2014). Spondyloarthritis: From disease phenotypes to novel treatments General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam ( Download date: 11 Jul 2018

2 Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis Jacqueline E. Paramarta 1, Leen De Rycke 1, Tanja F. Heijda 1, Carmen A. Ambarus 1, Koen Vos 1, Huib J. Dinant 1, Paul P. Tak 1,2, Dominique L. Baeten 1 1 Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands, 2 GlaxoSmithKline, Stevenage, UK Ann Rheum Dis Nov 1;72(11):1793-9

3 ABSTRACT Objectives To evaluate the efficacy and safety of adalimumab in patients with peripheral spondyloarthritis (SpA) not fulfilling the criteria for ankylosing spondylitis (AS) or psoriatic arthritis (PsA). Methods 40 patients with active peripheral SpA fulfilling the European Spondyloarthropathy Study Group or Amor criteria but not the criteria for AS or PsA were included in a randomised, double-blind, placebo-controlled clinical trial. Patients were treated 1 : 1 with adalimumab or placebo for 12 weeks, followed by an open label extension up to week 24. Safety and efficacy measurements were performed every weeks, with the patient s global assessment of disease activity at week 12 as the primary endpoint. Results At week 12, the patient s and physician s global assessment of disease activity, swollen joint count, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS) and erythrocyte sedimentation rate improved significantly in the adalimumab group compared with the baseline values and compared with placebo. A similar improvement was seen upon adalimumab treatment from weeks 12 to 24 in the patients originally randomised to placebo, whereas the clinical response was maintained or even augmented at week 24 in the patients who received adalimumab from the start. ASDAS inactive disease and BASDAI50 responses were met in 42% of the adalimumab group versus 0% 5% in the placebo group at week 12 (p=0.001 and p=0.008, respectively), and were further increased at week 24. The number of adverse events was not different between the adalimumab and placebo groups. Conclusions Adalimumab appears to be effective and well tolerated in SpA patients with peripheral arthritis, also in those patients not fulfilling the AS or PsA criteria. 82

4 INTRODUCTION The treatment of spondyloarthritis (SpA) has improved since the successful introduction of tumour necrosis factor (TNF)-blockade in this disease more than 10 years ago. 1-5 However, this therapy is only approved and reimbursed for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which are the best described and studied phenotypic subtypes of SpA. Approximately a third of the SpA population cannot be classified as AS or PsA and belong to one of the other SpA subtypes: inflammatory bowel disease related SpA, reactive arthritis and undifferentiated spondyloarthritis.,7 The last consists of patients with peripheral disease as well as patients with axial disease not fulfilling the modified New York criteria for AS, 8 now commonly called non-radiographic axial SpA (nr-axspa). Based on the similarities in symptoms and disease severity between nr-axspa and AS, 9 new classification criteria have been developed for axial SpA without phenotypic subclassifications. 10 Supporting the concept that nr-axspa is not fundamentally different from AS, several small placebo-controlled randomised clinical trials (RCTs) have demonstrated the efficacy of TNF-blockers in nr-axspa This has recently been confirmed in a large RCT with adalimumab. 14 As for axial SpA, familial aggregation studies, synovial immunopathology and experimental models 21 strongly suggest that also peripheral disease in SpA belongs to a single pathological entity. Accordingly, unifying criteria have recently been developed for peripheral SpA. 22 TNF-blockade has a proven beneficial effect on peripheral manifestations of AS and PsA. 3,4,23-2 In non-as and non-psa peripheral SpA, several small studies suggest a good efficacy of anti-tnf-therapy but RCTs are still lacking Therefore, the objective of this study was to assess the efficacy and safety of adalimumab in a randomised, double-blind, placebo-controlled clinical trial in patients with peripheral SpA not fulfilling the criteria for AS or PsA. METHODS Study design Overall, 40 patients were randomised (1 : 1) in a single centre, double-blind clinical trial to receive adalimumab 40 mg or placebo subcutaneously every other week for 12 weeks, followed by an open label extension with adalimumab for another 12 weeks. Written informed consent was obtained from each patient before study related procedures were performed. If eligible, patients entered the study within 3 weeks. The primary endpoint of the study was the improvement in the patient s global assessment of disease activity at week 12. This endpoint was chosen because most other disease activity measurements in SpA are validated in AS only and because it has been used previously as primary endpoint in anti-tnf trials in mixed SpA populations. 4 The study drug was provided in prefilled syringes containing adalimumab 40 mg or matching placebo (Abbott Laboratories, Abbott Park, Illinois, USA). The study was approved by the local Ethics Committee and is registered under the code NTR180. Adalimumab in peripheral SpA Patients Patients had to fulfil the European Spondyloarthropathy Study Group (ESSG) criteria and/or the Amor criteria 33 for SpA for at least 3 months without fulfilling the criteria for AS 8 or PsA

5 The Assessment of SpondyloArthritis International Society (ASAS) criteria for peripheral SpA 22 were not used as they were not published yet when the study was started. Patients had to be between 18 and 70 years old and had to have an active arthritis (at least one swollen and tender joint) despite treatment with non-steroidal anti-inflammatory drugs (NSAIDs). For female subjects, a negative pregnancy test and adequate contraception during the study and for 150 days thereafter were criteria for entry. Exclusion criteria included serious infections in the previous 4 weeks, history of malignancy in the past 10 years, significant history of other severe diseases or uncontrolled concomitant disease. Chest radiography and a tuberculin skin test were performed at screening. In case of active tuberculosis, patients were excluded and in case of latent tuberculosis, patients had to receive at least 3 months of isoniazide before enrolment. Concurrent and prior medication Patients were allowed to continue NSAIDs, corticosteroids ( 10 mg/day prednisone or equivalent), methotrexate and sulphasalazine provided that the dosage was stable for at least 4 weeks prior to baseline and throughout the study and, for methotrexate and sulphasalazine, provided they had been started at least 3 months before inclusion. Intra-articular corticosteroids and other disease-modifying antirheumatic drugs (DMARDs) were not allowed and were discontinued at least 4 weeks prior to baseline. Prior anti-tnf-therapy or investigational drugs were permitted if stopped more than 2 months prior to baseline. Clinical response Patients were seen for clinical evaluation at baseline, weeks, 12, 18 and 24 where the following disease activity parameters were evaluated: patient s and physician s global assessment of disease activity (each a 100 mm visual analogue scale), 8/ tender joint count (TJC) and swollen joint count (SJC), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 35 Ankylosing Spondylitis Disease Activity Score (ASDAS), 3 modified Schober index, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). Improvement at weeks 12 and 24 was also measured by the different ASDAS improvement criteria and BASDAI50 response The Health Assessment Questionnaire Disability Index (HAQ-DI) 39 and Health Utility Index Mark-3 (HUI-3) 40,41 were measured as disability and health related quality of life (QoL) variables. At each visit patients were asked for side effects, and routine laboratory testing and physical examination were performed for safety evaluation. Statistical analysis The sample size calculation was based on previous anti-tnf trials which included peripheral SpA 1,4,27 with an estimated response in patient s global assessment at week 12 of 48±24 mm in the adalimumab group and 21±32 mm in the placebo group, a power of 80% and α level of The data were tested for normal distribution and presented as mean±sd or SEM. Analysis of covariance (ANCOVA) adjusting for the baseline score was used to compare change from baseline at week 12 between the adalimumab and placebo groups. Further comparison of the adalimumab and placebo groups was done by independent sample t test for continuous 84

6 variables and χ 2 test for categorical variables. Changes from baseline (intragroup analysis) were assessed by paired t tests. All statistical tests were two-sided and p values of <0.05 were considered statistically significant. RESULTS Clinical and demographic characteristics at baseline In all, 40 patients were enrolled in the study and subsequently randomised to treatment with adalimumab or placebo. A total of 31 patients fulfilled both the ESSG and Amor criteria, six only the ESSG criteria, and three only the Amor criteria. The demographic and clinical characteristics were similar across both treatment arms (table 1). Only human leukocyte antigen B27 (HLA-B27) positivity tended to be higher in the adalimumab group (55%) versus the placebo group (25%) (p=0.053). At baseline, both treatment groups were well matched for all disease activity parameters except for the physician s global assessment, which was somewhat higher in the placebo group (57.0±12. mm) compared with the adalimumab group (47.8±11.8 mm) (p=0.022) (table 1). The mean SJC tended to be slightly higher in the patients who were assigned to adalimumab (4.3±4.2) compared with placebo (2.5±1.9) (p=0.09). The number of patients with elevated CRP (n=7 and n=8 in the adalimumab and placebo groups, respectively) and ESR (n=3 and n=4, respectively) at baseline was similar in the two groups. Concomitant NSAID and DMARD use was not different between the treatment groups. One patient randomised to receive adalimumab and two patients randomised to receive placebo had previously been treated with TNF-blockers (infliximab or adalimumab) for inflammatory bowel disease, but in all cases TNF-blockade was stopped more than 1 year prior to baseline. Two patients tested positive for latent tuberculosis and were treated with isoniazide before entering the trial. Adalimumab in peripheral SpA Improvement of disease activity at week 12 The primary endpoint of the study was met since the patient s global assessment showed a strong improvement at week 12 compared with baseline in the adalimumab group ( 31.0±23.3 mm), while the placebo group showed almost no improvement ( 5.9±21.4 mm) (p=0.001). Also the improvement in the physician s global assessment, BASDAI, ASDAS and ESR was significantly greater in the adalimumab treated patients compared with placebo (p<0.05 for all parameters) (table 2). These data were confirmed by direct comparison of the adalimumab and placebo groups: the patient s and physician s global assessment, BASDAI and ASDAS were significantly lower in adalimumab compared with placebo at week as well as at week 12 (figure 1). Moreover, the intragroup analysis demonstrated a strong and significant improvement at week 12 compared with baseline in the adalimumab group for the patient s and physician s global assessment, SJC, BASDAI and ASDAS (p<0.05 for all parameters) (table 3). In sharp contrast, none of these parameters showed any statistically significant change in the placebo group over this time period. The inflammatory parameters showed a numerical but non-significant decrease at week 12 of adalimumab treatment. Subanalysis of patients with increased CRP at baseline, however, showed that CRP levels decreased in seven out of seven patients treated with adalimumab. 85

7 0 Patient's global assessment 80 Placebo controlled Open label Physician's global assessment 80 Placebo controlled Open label 0 Adalimumab Placebo mm 40 mm 40 * 20 0 Week 0 Week * * Week 12 Week 18 Week Week 0 * Week * Week 12 Week 18 * Week 24 BASDAI 8 Placebo controlled Open label 4 Placebo controlled ASDAS Open label * * 1 * * 0 Week 0 Week Week 12 Week 18 Week 24 0 Week 0 Week Week 12 Week 18 Week 24 number of joints Swollen joint count Placebo controlled Open label Week 0 Week Week 12 Week 18 * Week 24 Back pain 8 Placebo controlled Open label Week 0 Week Week 12 Week 18 Week 24 Figure 1. Changes in the clinical disease activity parameters during treatment with adalimumab or placebo from week 0 until 12, and during the open label extension phase with adalimumab from week 12 until 24. The panel represents the patient s and physician s global assessment of disease activity on a 100 mm visual analogue scale (VAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), swollen joint count, and back pain score (assessed by BASDAI question #2). Data are presented as mean (standard error of the mean). * P <0.05 compared to placebo by independent sample t-test. 8

8 Table 1. Baseline characteristics of the study population by treatment group Adalimumab (n=20) Placebo (n=20) Age, mean (SD) years 41.5 (12.8) 44.4 (11.1) Disease duration, mean (SD) years 7.9 (9.3).7 (.2) Number of men/women 9/11 12/8 BMI, mean (SD) kg/m (4.2) 2.8 (5.7) HLA-B27 positive, n (%) 11 (55) 5 (25) Subtype USpA, n (%) 15 (75) 17 (85) Subtype ReA, n (%) 4 (20) 0 (0) Subtype IBD-SpA, n (%) 1 (5) 3 (15) Inflammatory back pain (history/presence), n (%) 1 (80) 15 (75) Enthesitis (history/presence), n (%) 15 (75) 15 (75) Dactylitis (history/presence), n (%) 4 (20) 1 (5) Patient s global assessment, mm VAS 5.8 (18.1) 8.4 (17.4) Physician s global assessment, mm VAS 47.8 (11.8) 57.0 (12.)* Swollen joint count, 0- joints 4.3 (4.2) 2.5 (1.9) Tender joint count, 0-8 joints 9.4 (8.2) 10. (5.9) BASDAI 5.5 (2.3).0 (1.4) ASDAS 2.9 (1.0) 3.2 (0.9) CRP, mg/l 7.8 (13.3) 13.5 (2.4) ESR, mm/hour 11. (13.5) 15.7 (23.1) Concomitant NSAIDs, n (%) 13 (5) 14 (70) Concomitant corticosteroids, n (%) 0 (0) 2 (10) Concomitant MTX, n (%) 5 (25) (30) Concomitant SSZ, n (%) 7 (35) 4 (20) Previous anti-tnf-treatment, n (%) 1 (5) 2 (10) Adalimumab in peripheral SpA BMI = body mass index; USpA = undifferentiated spondyloarthritis; ReA = reactive arthritis; IBD-SpA = inflammatory bowel disease related spondyloarthritis; VAS = visual analogue scale; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; ASDAS = Ankylosing Spondylitis Disease Activity Score; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NSAIDs = non-steroidal anti-inflammatory drugs; MTX = methotrexate; SSZ = sulphasalazine; TNF = tumour necrosis factor. Significance of the comparisons is determined by independent sample t-test for continuous variables and χ 2 test for categorical variables. * P <0.05 compared to the adalimumab group. Improvement of disease activity at week 24 After the 12-week placebo-controlled phase all patients were treated in an open label phase with adalimumab for an additional 12 weeks. In the original placebo group, adalimumab treatment induced a significant decrease of all clinical disease activity parameters between weeks 12 and 24 (p<0.05 for all parameters) (table 3 and figure 1). Additionally, ESR was significantly suppressed (p<0.05). Analysis of patients with increased CRP at baseline showed a decrease in four out of five patients during this treatment period. 87

9 Table 2. Mean changes in disease activity from baseline to week 12 by treatment group Baseline to week 12 Adalimumab (n=19) Placebo (n=19) P-value Patient s global assessment, mm VAS 31.0 (23.3) 5.9 (21.4) Physician s global assessment, mm VAS 19.8 (19.5) 4.1 (1.4) Swollen joint count, 0- joints 2.5 (4.0) 0.4 (1.8) Tender joint count, 0-8 joints 1.8 (9.2) 1.7 (.5) BASDAI 1.8 (2.) 0.3 (1.5) ASDAS 1.1 (1.2) 0.0 (0.9) CRP, mg/l 5.7 (12.4) 4.0 (22.9) ESR, mm/hour.0 (12.5) 1.7 (9.3) Values are the mean change (standard deviation) from baseline to week 12. VAS = visual analogue scale; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; ASDAS = Ankylosing Spondylitis Disease Activity Score; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate. Significance of the comparisons is determined by analysis of covariance (ANCOVA) adjusted for baseline, comparing adalimumab with placebo treatment. In the patients who already received adalimumab from baseline, we observed a further improvement of all clinical disease activity parameters between weeks 12 and 24, reaching statistical significance for physician s global assessment, SJC and BASDAI (table 3 and figure 1). All clinical disease activity parameters as well as ESR were significantly improved at week 24 in comparison with baseline. ASDAS and BASDAI response criteria Although the trial was designed to assess the effect of adalimumab on peripheral SpA, 22 out of 40 patients had also axial complaints at baseline. As we observed a significant effect on BASDAI and ASDAS scores (tables 2, 3 and figure 1), we additionally assessed the ASDAS and BASDAI response criteria. At week 12, 53% of the patients treated with adalimumab met the criteria for ASDAS clinically important improvement, 42% the criteria for ASDAS inactive disease and 42% a BASDAI50 response (figure 2). All three assessments reached statistical significance compared with placebo, which showed an ASDAS improvement of 11%, ASDAS inactive disease of 0% and BASDAI50 response of 5%. By 24 weeks, the initial placebo treated group showed a similar response to 12 weeks of adalimumab treatment: ASDAS clinically important improvement, ASDAS inactive disease and BASDAI50 response were reached in 35% for all three parameters (figure 2). In the group receiving adalimumab from the beginning, treatment with adalimumab for an additional 12 weeks even further increased the percentage of patients who reached the ASDAS clinically important improvement, ASDAS inactive disease and BASDAI50 response to 3%, 58% and 53%, respectively (figure 2). Improvement in disability and QoL measurements To assess the impact of adalimumab treatment on disability and QoL, we measured the HAQ-DI and the HUI-3. As shown in table 3, an improvement in HAQ-DI was observed at week 12 in the 88

10 Table 3. Disease activity parameters at week 0, 12 and 24 by treatment group Adalimumab week 0-24 Placebo week 0-12 Adalimumab week week 24 (n=17) week 12 (n=19) week 0 (n=20) week 24 (n=19) week 12 (n=19) week 0 (n=20) Patient s global assessment, mm VAS 5.8 (18.1) 33.3 (2.)* 22.5 (20.2)* 8.4 (17.4) 2.2 (21.5) 34.9 (25.7)* Physician s global assessment, mm VAS 47.8 (11.8) 28.4 (20.9)* 18.4 (14.8)* 57.0 (12.) 52.1 (18.9) 33.8 (21.0)* Swollen joint count, 0- joints 4.3 (4.2) 1.9 (2.2)* 0. (1.0)* 2.5 (1.9) 2.2 (1.1) 1.3 (0.8)* Tender joint count, 0-8 joints 9.4 (8.2) 7.9 (14.0) 4. (.9)* 10. (5.9) 12. (8.8) 7.8 (7.0) BASDAI 5.5 (2.3) 3.8 (3.2)* 2.5 (2.1)*.0 (1.4) 5.7 (1.7) 3. (2.4)* ASDAS 2.9 (1.0) 1.8 (1.2)* 1.4 (0.8)* 3.2 (0.9) 3.1 (0.9) 1.9 (0.9)* CRP, mg/l 7.8 (13.3) 2.5 (2.2) 2.1 (2.8) 13.5 (2.4) 12.8 (24.7) 7.9 (24.0) ESR, mm/hour 11. (13.5).1 (7.2) 4.9 (2.7)* 15.7 (23.1) 13.1 (13.7) 4.1 (2.) HAQ-DI 0.8 (0.) 0. (0.7)* 0.4 (0.)* 1.1 (0.5) 1.0 (0.4) 0. (0.4)* HUI (0.35) 0.0 (0.40) 0.7 (0.3)* 0.38 (0.28) 0.4 (0.34) 0.59 (0.31)* Values are the mean (standard deviation). VAS = visual analogue scale; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; ASDAS = Ankylosing Spondylitis Disease Activity Score; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; HAQ-DI = Health Assessment Questionnaire Disability Index; HUI-3 = Health Utility Index Mark 3. Significance of the comparisons is determined by a paired t-test. * P <0.05 compared to week 0 (by treatment group). P <0.05 week 24 compared to week 12 (by treatment group). Adalimumab in peripheral SpA 89

11 Improvement at week 12 Improvement at week 24 % of patients * * * % of patients ASDAS improvement ASDAS inactive disease BASDAI50 response 0 Adalimumab (n=19) Placebo (n=19) 0 Adalimumab (n=19) Placebo/Adalimumab (n=17) Figure 2. Percentages of patients who achieved a clinically important improvement and inactive disease according to the Ankylosing Spondylitis Disease Activity Score (ASDAS) criteria, and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response at week 12 and week 24. The first 12 weeks patients received either adalimumab or placebo, the last 12 weeks all the patients received adalimumab in the open label extension phase. * P<0.05 compared to placebo by χ 2 test. adalimumab group but not the placebo group. A similar trend was seen for the HUI-3. At week 24, both parameters were significantly improved in both treatment arms (p<0.05 for both parameters). Dropouts and safety analysis The safety analysis is summarised in table 4. In each treatment arm, 19 patients completed the 12-week placebo-controlled phase. Two patients discontinued the study because of a serious adverse event (SAE): one death due to suicide in the adalimumab group and one arthroscopy related septic arthritis in the placebo group. No other SAEs were observed. The number of nonserious adverse events (AEs) was similar (n=12 in each group). The number of infectious events was lower in the adalimumab group (n=4) than in the placebo group (n=8). Two adalimumab treated patients developed a diffuse skin rash, which resolved after topical corticosteroids and oral antihistaminic treatment, and did not result in treatment discontinuation. In the open label phase, all 19 patients from the group originally treated with adalimumab completed the full study. In the group initially randomised to receive placebo, 17 patients completed the open extension until week 24: one patient dropped out due to a SAE (hospital admission because of an acute psychosis) and one patient was lost to follow-up. There were no other SAEs. Non-serious AEs included 13 infections, consisting mainly of upper respiratory tract infections and cystitis, and one local injection reaction, which resolved spontaneously. Overall, there were no unexpected safety signals. DISCUSSION The present randomised double-blind, placebo-controlled clinical trial demonstrated the efficacy and safety of adalimumab in patients with active peripheral SpA not fulfilling the criteria for AS or PsA. The primary objective of the study was met as there was a rapid and significant decrease in the patient s global assessment upon adalimumab but not placebo treatment. Additionally, treatment 90

12 with adalimumab but not with placebo, significantly improved all other clinical parameters of disease activity except the TJC8, which showed a numerical but not significant decrease. The efficacy of adalimumab in this patient group was confirmed by three additional observations. First, ESR and CRP as objective measurements of inflammation did consistently decrease in those patients with elevated values at baseline. Second, the patients who were initially treated with placebo also showed good efficacy upon treatment with adalimumab in the open label phase. And third, the clinical benefit of TNF-blockade was sustained and even augmented on weeks 18 and 24 in the group continuously treated with adalimumab. Moreover, multiple regression analysis (data not shown) showed that features such as gender, HLA-B27 status, CRP, ESR, SJC and concomitant DMARD treatment did not act as confounders in this trial. These data are in agreement with the reported efficacy of adalimumab in large RCTs in AS 42 and PsA, 24 as well as in smaller trials in other SpA subtypes. 1,4,11-13,27-32 Taken together, these trials support the concept that anti-tnf-therapy is highly effective in SpA as a whole independent of the phenotypic manifestation. This concept is further strengthened by the significant improvement of measurements primarily developed for axial disease such as BASDAI and ASDAS despite the fact that the trial was designed for peripheral SpA. The efficacy of adalimumab on these parameters in our study is similar to that reported for AS in the ATLAS trial: a BASDAI50 response at week 12 was achieved in 42% of our study population compared with 45% reached in the Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) trial, 42 whereas at week 24, ASDAS inactive disease was reached in respectively 58% and 55% of the patients. 43 The results of our trial raise three additional issues with regard to peripheral SpA. First, we used the ESSG and Amor criteria as the ASAS criteria for peripheral SpA were not published yet when the study was started. Post hoc application of these criteria to our study population, however, indicated that 38 out of the 40 patients also fulfilled the ASAS criteria for peripheral SpA. Albeit presenting primarily with peripheral disease, 22 out of 40 patients also had inflammatory back pain when actively questioned for axial complaints. Whereas strict application of the ASAS criteria would thus imply that the criteria for axial SpA should be used rather than peripheral SpA, the overlap in signs and symptoms between different SpA phenotypes observed in the present study fits with the significant improvement in BASDAI and ASDAS in these patients with predominantly peripheral SpA, and indicates that the subclassification in axial versus peripheral SpA may not always completely cover the clinical picture. It remains to be determined whether global measurements such as patient s and physician s global assessment, 1,4 peripheral measurements such as SJC, or primarily axial measurements such as BASDAI and ASDAS are the most appropriate to monitor disease activity in SpA patients with a mixed phenotype. A second issue is whether the improvement in disease activity also translates in improved function and QoL in non-as, non-psa peripheral SpA. Functional outcome parameters have been developed and validated for AS and are also applied to axial SpA but similar parameters are not available for peripheral SpA. Interestingly, also at the functional level we noticed a significant improvement of axial outcome parameters such as the lumbar mobility measured by the modified Schober index in these patients presenting primarily with peripheral disease (data not shown). As to disability and QoL, both the HAQ-DI and the HUI-3 were significantly improved at week 24. This has medical and socio-economic implications as previous studies in AS have indicated that QoL scores are associated with working status and thus with economic and societal costs. 44 Adalimumab in peripheral SpA 91

13 Table 4. Adverse events through week 24 by treatment group Adalimumab Week 0-12 Placebo Number of patients with AEs Total number of AEs Infections Common cold 4 3 Gingivitis 0 1 Cystitis 0 2 Septic arthritis 0 1 Dermatomycosis 0 1 Skin Diffuse rash 2 0 Other 0 2 Gastrointestinal Nausea 1 0 Psychologic Depression 1 0 Other 4 2 Total number of SAEs 1 1 Death 1 0 Hospital admission 0 1 A third issue is that the peripheral SpA patients included in the study presented with arthritis rather than dactylitis or enthesitis (table 1). The low frequency of dactylitis, with only three patients having active dactylitis at baseline, may be related to the fact that we excluded patients fulfilling the ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria for PsA. In contrast, enthesitis was noted in the history of 75% of the patients. However, only 25% of the patients had active enthesitis at inclusion, thereby precluding a detailed analysis of this manifestation in our trial. However, a previous study including specifically SpA patients with refractory heel enthesitis has indicated the efficacy of TNF-blockade by etanercept for this peripheral SpA manifestation. 45 The number of SAEs, AEs and infections was similar in the adalimumab treated patients compared with the placebo treated patients. The number of SAEs was quite high in our cohort (three out of 40 patients) but two out of three SAEs (suicide and acute psychosis) were not considered to be related to the study drug. The third SAE, a septic arthritis, was most probably triggered by needle arthroscopy and occurred in the placebo group and not the adalimumab group. Although safety data remain difficult to interpret correctly in relatively small proof-ofconcept trials, we did not observe unexpected safety signals. In conclusion, the results of this randomised double-blind, placebo-controlled clinical trial indicate that SpA patients with peripheral disease who do not fulfil the criteria for AS or PsA may 92

14 Table 4. Continued Adalimumab Week Number of patients with AEs 8 11 Total number of AEs 9 13 Infections Skin Common cold 3 3 Sinusitis 0 1 Otitis 0 1 Tooth abcess 1 1 Cystitis 0 3 Injection-site reaction 0 1 Other 0 1 Gastrointestinal Diarrhea 0 1 Bloating 1 0 Psychologic Depression 1 0 Psychosis 0 1 Other 3 0 Total number of SAEs 0 1 Hospital admission 0 1 Values are the number of events. Patients may be counted in more than 1 adverse event category and may be counted more than once within one sort adverse event. AE = adverse event; SAE = serious adverse event. Adalimumab in peripheral SpA benefit from adalimumab treatment in terms of disease activity and QoL. This warrants further confirmation in larger studies. Acknowledgements We thank Abbott for the supply of the study medication for this investigator initiated and independent study. Also we would like to thank the following rheumatologists for referring patients: Dr ZN Jahangier, Dr G Collee, Dr MHW de Bois and Drs A van Sijl. We thank AN Scholten, A van Tillo, Dr DM Gerlag, R Heinrich, A Giesbers and L Gomes for their help in this study, and Professor Dr R Landewé for critical reading of the manuscript. Professor Dr DL Baeten is supported by a Vidi grant from The Netherlands Organization for Scientific Research (NWO). 93

15 REFERENCES 1 Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59: Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43: Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;35: Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;4: Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: Dougados M, Van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34: Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377: Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27: Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;0: Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;8: Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58: Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum 2009;0: Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48- week randomised controlled trial. Ann Rheum Dis 2011;70: Sieper J, Van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results o a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72: Said-Nahal R, Miceli-Richard C, D Agostino MA, et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum 2001;45: Said-Nahal R, Miceli-Richard C, Berthelot JM, et al. The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Francais d Etude Genetique des Spondylarthropathies. Arthritis Rheum 2000;43: Porcher R, Said-Nahal R, D Agostino MA, et al. Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum 2005;53: Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009;0: Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012;4: Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 200;54: Rudwaleit M, Van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:

16 23 Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;4: Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum 2005;52: Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective singlecentre study. Arthritis Res Ther 2004;:R Van Kuijk AW, Gerlag DM, Vos K, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 2009;8: Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005;52: Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002;29: Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the antitumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004;31: Marzo-Ortega H, McGonagle D, O Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44: Marzo-Ortega H, McGonagle D, O Connor P, et al. Efficacy of etanercept for treatment of Crohn s related spondyloarthritis but not colitis. Ann Rheum Dis 2003;2: Meyer A, Chatelus E, Wendling D, et al. Safety and efficacy of anti-tumor necrosis factor alpha therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011;3: Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990;57: Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 200;54: Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;8: Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70: Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-tnf agents in patients with ankylosing spondylitis. Ann Rheum Dis 200;5: Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23(Suppl 39):S Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33: Gooch K, Feeny D, Wong RL, et al. Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis? Value Health 2011;14: Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 200;54: Sieper J, Van der Heijde D, Dougados M, et al. Early response to adalimumab predicts longterm remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71: Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, healthrelated quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010;37: Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebocontrolled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010;9: Adalimumab in peripheral SpA 95